| Literature DB >> 34653429 |
Sara Adibfar1, Marischa Elveny2, Hadisha Sh Kashikova3, Maria Vladimirovna Mikhailova4, Pooya Farhangnia5, Sajjad Vakili-Samiani6, Hanieh Tarokhian7, Farhad Jadidi-Niaragh8.
Abstract
Due to its high occurrence and mortality rate, breast cancer has been studied from various aspects as one of the cancer field's hot topics in the last decade. Epigenetic alterations are spoused to be highly effective in breast cancer development. Enhancer of zeste homolog 2 (EZH2) is an enzymatic epi-protein that takes part in most vital cell functions by its different action modes. EZH2 is suggested to be dysregulated in specific breast cancer types, particularly in advanced stages. Mounting evidence revealed that EZH2 overexpression or dysfunction affects the pathophysiology of breast cancer. In this review, we discuss biological aspects of the EZH2 molecule with a focus on its newly identified action mechanisms. We also highlight how EZH2 plays an essential role in breast cancer initiation, progression, metastasis, and invasion, which emerged as a worthy target for treating breast cancer in different approaches.Entities:
Keywords: Breast cancer; EZH2; Targeted-therapy
Mesh:
Substances:
Year: 2021 PMID: 34653429 DOI: 10.1016/j.lfs.2021.120047
Source DB: PubMed Journal: Life Sci ISSN: 0024-3205 Impact factor: 5.037